MAPT and Alzheimer disease: The substantial progression observed on the CDR, CFI and ADL scales, measures of clinically meaningful change, among A4 participants with higher levels of amyloid and tau pathology, compared to the minimal decline seen in LEARN support the feasibility of establishing clinical efficacy of candidate therapeutics in the preclinical AD population.